Similarly, HS-345, an inhibitor targeting tropomyosin-related kinase A, and HS-527, an inhibitor of PI3K, inhibit angiogenesis via targeting HIF-1α/VEGF axis in pancreatic cancer [95, 96]. This evidence concerns the gene HIF1A and pancreatic neoplasm.